[go: up one dir, main page]

PE20020101A1 - Metodo para la preparacion de composiciones - Google Patents

Metodo para la preparacion de composiciones

Info

Publication number
PE20020101A1
PE20020101A1 PE2001000603A PE2001000603A PE20020101A1 PE 20020101 A1 PE20020101 A1 PE 20020101A1 PE 2001000603 A PE2001000603 A PE 2001000603A PE 2001000603 A PE2001000603 A PE 2001000603A PE 20020101 A1 PE20020101 A1 PE 20020101A1
Authority
PE
Peru
Prior art keywords
methyl
sodium
dispersion
homogeneous
compositions
Prior art date
Application number
PE2001000603A
Other languages
English (en)
Inventor
Marco Schroeder
Patrick Busson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020101A1 publication Critical patent/PE20020101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN METODO PARA PREPARAR COMPOSICIONES QUE COMPRENDE: a)PREPARAR UNA SOLUCION O DISPERSION HOMOGENEA DE UN LIQUIDO Y UN COMPUESTO TAL COMO OSELTAMIVIR o (5-[7-[2-(5-METIL-2-FENIL-OXAZOL-4-IL)-ETOXI]-BENZOTIOFEN-4-METIL]-2,4-TIAZOLIDINDIONA o UN INHIBIDOR DE LIPASAS COMO ORLISTAT; EXCIPIENTES QUE CONTIENEN UN MATERIAL DE RECUBRIMIENTO O FORMADOR DE UNA PASTA VITREA COMO POLIOL (MALTODEXTRINA, TREHALOSA, MALTITOL, GLUCOSA, ENTRE OTROS), GOMA O POLIMERO (POLIENTIELENGLICOL, ALMIDON, CELULOSA, POVIDONA, ENTRE OTROS), TENSIOACTIVO (LAURILSULFATO DE SODIO, DOCUSATO DE SODIO, CASEINATO DE SODIO, SALES DE ACIDO GRASO, ENTRE OTROS); b)EXPANSION DE LA SOLUCION O DISPERSION HOMOGENEA QUE DESARROLLA UN VOLUMEN Y SUPERFICIE MAYORES MEDIANTE UN CAMBIO (DISMINUCION) DE LA PRESION ENTRE 30 Y 150 TORR SIN LLEGAR A LA EBULLICION; c)SECADO O ENFRIADO. LA COMPOSICION SE CARACTERIZA POR TENER UN NIVEL DE SOLVENTE RESIDUAL ENTRE 0,1%p/p Y 10%p/p; DENSIDAD APARENTE (POR VERTIDO) ENTRE 0,1g/cm3 Y 0,9g/cm3; TAMANO DE PARTICULAS ENTRE 50µm Y 600µm
PE2001000603A 2000-06-27 2001-06-21 Metodo para la preparacion de composiciones PE20020101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00113535 2000-06-27

Publications (1)

Publication Number Publication Date
PE20020101A1 true PE20020101A1 (es) 2002-02-12

Family

ID=8169074

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000603A PE20020101A1 (es) 2000-06-27 2001-06-21 Metodo para la preparacion de composiciones

Country Status (37)

Country Link
US (3) US6534087B2 (es)
EP (1) EP1296656B1 (es)
JP (2) JP4149803B2 (es)
KR (1) KR100557845B1 (es)
CN (1) CN1236764C (es)
AR (1) AR029278A1 (es)
AT (1) ATE334662T1 (es)
AU (2) AU2001281846B2 (es)
BR (1) BRPI0112014B1 (es)
CA (1) CA2411153C (es)
CY (1) CY1105714T1 (es)
CZ (1) CZ301813B6 (es)
DE (1) DE60121953T2 (es)
DK (1) DK1296656T3 (es)
EC (1) ECSP024401A (es)
EG (1) EG24141A (es)
ES (1) ES2269441T3 (es)
HR (1) HRP20021009B1 (es)
HU (1) HU229550B1 (es)
IL (2) IL153282A0 (es)
JO (1) JO2247B1 (es)
MA (1) MA26922A1 (es)
ME (1) MEP90608A (es)
MX (1) MXPA02012583A (es)
MY (1) MY129798A (es)
NO (1) NO332181B1 (es)
NZ (1) NZ523024A (es)
PE (1) PE20020101A1 (es)
PL (1) PL203804B1 (es)
PT (1) PT1296656E (es)
RU (1) RU2244542C2 (es)
SI (1) SI1296656T1 (es)
TW (1) TWI278325B (es)
UY (1) UY26799A1 (es)
WO (1) WO2002000201A2 (es)
YU (1) YU96602A (es)
ZA (1) ZA200209649B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
EP1296656B1 (en) * 2000-06-27 2006-08-02 F. Hoffmann-La Roche Ag Method for preparing a composition
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
ATE453390T1 (de) * 2002-04-26 2010-01-15 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
KR100517072B1 (ko) * 2002-11-25 2005-09-26 주식회사 태평양 폴리올/고분자 마이크로캡슐 및 이를 이용한 효소 안정화방법
US9174176B2 (en) 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
US8030362B2 (en) * 2003-12-12 2011-10-04 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
CA2562213A1 (en) * 2004-04-06 2005-11-24 Rpg Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
WO2006030784A1 (ja) * 2004-09-15 2006-03-23 Banyu Pharmaceutical Co., Ltd. サンプリング方法、サンプリング装置、ｌｏｇＤ測定方法及びｌｏｇＤ測定システム
US20100015057A1 (en) * 2004-12-31 2010-01-21 Mikhail Yurievich Gotovskiy Magnetoresonance preparations, device for individually selecting said preparations for increasing an organism life activity in actual environmental conditions
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US7984717B2 (en) * 2005-04-29 2011-07-26 Medtronic, Inc. Devices for augmentation of lumen walls
US20070060610A1 (en) * 2005-06-16 2007-03-15 Wempe Michael F Methods and pharmaceutical formulations for increasing bioavailability
WO2006136196A1 (en) * 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
WO2006136197A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Smoking device incorporating a breakable capsule, breakable capsule and process for manufacturing said capsule
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
WO2007046102A2 (en) 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
FR2895908B1 (fr) * 2006-01-12 2008-03-28 France Etat Procede de fabrication d'une forme pharmaceutique de phosphate d'oseltamivir
ZA200806356B (en) 2006-02-20 2009-11-25 Chugai Pharmaceutical Co Ltd Pharmaceutical composition comprising oseltamivir phosphate
US7903256B2 (en) 2006-03-16 2011-03-08 Duke University Methods, systems, and computer program products for performing real-time quadrature projection based Fourier domain optical coherence tomography
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100812824B1 (ko) 2006-09-27 2008-03-12 주식회사 제닉 키토산과 폴리에틸렌글리콜을 이용한 생체친화성 저독성필름
EP2117354B1 (en) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. A dry food product containing live probiotic
CA2686286A1 (en) * 2007-05-18 2008-11-27 Tti Ellebeau, Inc. Transdermal delivery devices assuring an improved release of an active principle through a biological interface
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
WO2009050720A1 (en) * 2007-10-15 2009-04-23 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
US9623094B2 (en) 2009-03-27 2017-04-18 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
DK2435554T3 (en) 2009-05-26 2017-10-30 Advanced Bionutrition Corp STABLE DRY POWDER COMPOSITION WITH BIOLOGICALLY ACTIVE MICRO-ORGANISMS AND / OR BIOACTIVE MATERIALS AND PROCEDURES FOR ITS PREPARATION
EP2482802A4 (en) * 2009-09-29 2013-08-07 Michael Burnet NEW PESTICIDE FORMULATIONS
KR100940745B1 (ko) * 2009-10-15 2010-02-04 광동제약 주식회사 오를리스타트 및 아타풀지트 함유 복합제의 코팅펠렛 및 이를 이용한 제제
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
CN102725393B (zh) 2010-01-28 2015-12-02 先进生物营养公司 包含生物活性材料的干燥玻璃质组合物
KR101021030B1 (ko) * 2010-03-25 2011-03-09 엘지이노텍 주식회사 형광체 코팅방법, 발광장치 제조방법 및 코팅된 형광체
RU2579972C2 (ru) * 2010-04-07 2016-04-10 Мицубиси Гэс Кемикал Компани, Инк. Стабильная при хранении содержащая s-аденозил-l-метионин композиция высушенных дрожжей и способ ее производства
PL2603100T3 (pl) 2010-08-13 2019-06-28 Advanced Bionutrition Corp. Kompozycja stabilizująca przechowywanie na sucho materiałów biologicznych
CA2816119C (en) * 2010-10-29 2019-03-05 Western University Of Health Sciences Ternary mixture formulations
WO2012125297A1 (en) 2011-03-01 2012-09-20 The Procter & Gamble Company Porous disintegratable solid substrate for personal health care applications
BR112014023234B1 (pt) 2012-03-23 2020-12-08 Advanced Bionutrition Corporation composição de estabilização seca em um estado vítreo amorfo para um material bioativo, método para produzir a referida composição e produtos preparados com a mesma
CN103222964B (zh) * 2013-01-29 2014-10-08 青岛大学 一种奥利司他口服制剂及其制备方法
GB2524496A (en) * 2014-03-24 2015-09-30 British Airways Plc Dynamic tracking and control of passenger travel progress
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
CN107849597B (zh) 2015-06-25 2022-07-26 原生微生物股份有限公司 基于分析异质微生物群落形成活性微生物菌株的群的方法
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
PT3328215T (pt) 2015-07-29 2021-08-03 Advanced Bionutrition Corp Composições probióticas estáveis secas para utilizações dietéticas especiais
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物
EP3562955A4 (en) 2016-12-28 2020-08-12 Ascus Biosciences, Inc. METHODS, APPARATUS AND SYSTEMS FOR THE ANALYSIS OF STRAINS OF MICRO-ORGANISMS OF HETEROGENEOUS COMMUNITIES COMPLEX WITH TRACEOR ANALYZES, DETERMINATION OF THEIR INTERACTIONS AND FUNCTIONAL RELATIONSHIPS, AND SUMMARY OF MICROBIAL SETS OF MICROBIAL SETS AND MICROBIAL SETS INCLUDING MICROBIAL SETS AND INGREDIENTS
JP2020504620A (ja) 2016-12-28 2020-02-13 アスカス バイオサイエンシーズ， インコーポレイテッド 複雑な不均一コミュニティの完全微生物株の解析、その機能的関連性及び相互作用の決定、ならびにそれに基づく生物反応性の改変剤の同定及び合成、のための方法、装置、及びシステム
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem SOLID GALENIC FORM, MOLDED, GASTRIC RETENTION AND EXTENDED RELEASE AND METHOD OF PREPARING THE SAME

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
US4489438A (en) * 1982-02-01 1984-12-18 National Data Corporation Audio response system
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
EP0553777B1 (en) 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
US5560921A (en) 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
JP3722294B2 (ja) * 1993-02-23 2005-11-30 ワーナー−ランバート・コンパニー 実質的にアルコールを含有しない医薬組成物の製造方法
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5536264A (en) * 1993-10-22 1996-07-16 The Procter & Gamble Company Absorbent composites comprising a porous macrostructure of absorbent gelling particles and a substrate
US5523106A (en) * 1994-02-03 1996-06-04 Nabisco, Inc. Juice-based expanded snacks and process for preparing them
EP0976734B1 (en) 1995-02-27 2005-09-28 Gilead Sciences, Inc. Selective inhibitors of viral or bacterial neuraminidase
KR100447096B1 (ko) 1995-02-27 2005-10-11 갈리드사이언스인코오퍼레이티드 바이러스성또는세균성뉴라미니다제의신규한선택적저해제
WO1996040077A2 (en) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
EP0893992B1 (en) * 1996-04-16 2004-03-03 Novartis Consumer Health S.A. Fast disintegrating oral dosage form
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
WO1998016204A1 (en) * 1996-10-14 1998-04-23 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JPH11137208A (ja) 1997-11-14 1999-05-25 Nikken Chem Co Ltd 口腔内速溶性固形物及びその製造方法
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
ES2272066T3 (es) * 1998-04-09 2007-04-16 F. Hoffmann-La Roche Ag Proceso para la manufactura de particulas con tamaño de (sub)micras por disolucion de gas comprimido y surfactantes.
AU759388B2 (en) 1998-08-14 2003-04-10 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors and chitosan
PT1105122E (pt) 1998-08-14 2005-08-31 Hoffmann La Roche Composicoes farmaceuticas que contem inibidores de lipase
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
GB9904629D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
FR2791569B1 (fr) * 1999-03-31 2003-05-09 Pf Medicament Composition ou structure microporeuse expansee isotrope a dissolution rapide a usage pharmaceutique, veterinaire, dietetique, alimentaire ou cosmetique et son procede d'obtention
EP1296656B1 (en) * 2000-06-27 2006-08-02 F. Hoffmann-La Roche Ag Method for preparing a composition

Also Published As

Publication number Publication date
DE60121953T2 (de) 2007-03-08
EP1296656B1 (en) 2006-08-02
KR20030023880A (ko) 2003-03-20
PL365803A1 (en) 2005-01-10
AU2001281846B2 (en) 2006-04-27
KR100557845B1 (ko) 2006-03-10
MA26922A1 (fr) 2004-12-20
JP4149803B2 (ja) 2008-09-17
JO2247B1 (en) 2004-10-07
HRP20021009A2 (en) 2004-02-29
YU96602A (sh) 2005-03-15
EP1296656A2 (en) 2003-04-02
RU2244542C2 (ru) 2005-01-20
SI1296656T1 (sl) 2006-12-31
WO2002000201A3 (en) 2002-04-18
NO20026197D0 (no) 2002-12-23
PL203804B1 (pl) 2009-11-30
ME00672B (me) 2011-12-20
HUP0302060A2 (hu) 2003-09-29
US7074431B2 (en) 2006-07-11
CY1105714T1 (el) 2010-12-22
ECSP024401A (es) 2003-02-06
HUP0302060A3 (en) 2006-07-28
BRPI0112014B1 (pt) 2016-09-13
US20030039614A1 (en) 2003-02-27
CA2411153A1 (en) 2002-01-03
HRP20021009B1 (hr) 2011-07-31
AU8184601A (en) 2002-01-08
HU229550B1 (en) 2014-01-28
CN1438880A (zh) 2003-08-27
CZ301813B6 (cs) 2010-06-30
MY129798A (en) 2007-04-30
DK1296656T3 (da) 2006-11-27
NZ523024A (en) 2004-08-27
ES2269441T3 (es) 2007-04-01
US6534087B2 (en) 2003-03-18
ZA200209649B (en) 2004-03-10
JP2004501184A (ja) 2004-01-15
CN1236764C (zh) 2006-01-18
TWI278325B (en) 2007-04-11
CZ2003212A3 (cs) 2003-06-18
PT1296656E (pt) 2006-12-29
HK1058314A1 (en) 2004-05-14
MEP90608A (bs) 2011-12-20
NO20026197L (no) 2002-12-23
US20060134205A1 (en) 2006-06-22
DE60121953D1 (de) 2006-09-14
NO332181B1 (no) 2012-07-16
UY26799A1 (es) 2001-12-28
IL153282A0 (en) 2003-07-06
CA2411153C (en) 2007-01-30
ATE334662T1 (de) 2006-08-15
JP2007302683A (ja) 2007-11-22
IL153282A (en) 2008-03-20
MXPA02012583A (es) 2003-04-10
WO2002000201A2 (en) 2002-01-03
AR029278A1 (es) 2003-06-18
BR0112014A (pt) 2003-05-13
EG24141A (en) 2008-08-06
US20020018812A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
PE20020101A1 (es) Metodo para la preparacion de composiciones
PL346714A1 (en) Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications
PE63299A1 (es) Una dispersion acuosa de un solido particulado que tiene una superficie externa hidrofobica y peliculas producidas por la misma
SE8404804D0 (sv) Forfarande for framstellning av farmaceutiska kompositioner med fordrojd frigoring och med en hog halt aktiv bestandsdel
BR0002558A (pt) Processo para preparar uma composição de copolìmero intrinsecamente condutor, composição, e, processo para uso de um copolìmero intrinsecamente condutor
CO5040140A1 (es) Composiciones detergentes para superficies duras que comp- prenden un polimero hidrofilo a nivel muy bajo que atenua el esfuerzo cortante
AR014583A1 (es) Composicion de agente tensioactivo capaz de estructurar una composicion liquida no acuosa y particula estructurante que la comprende
MX165822B (es) Detergente mas suavizador con ingredientes de imidazolina
FR2443502A1 (fr) Comprime detergent comportant un enrobage de sel hydrate et procede de preparation du comprime
CA2426764A1 (en) Nateglinide-containing hydrophilic pharmaceutical preparation
ES2146064T3 (es) Metodo de producir un producto repelente del agua, y producto y metodo para impermeabilizar una superficie de un material de construccion.
KR20130015469A (ko) 개선된 제형 안정도를 갖는 워시오프 화장료 조성물
ES534215A0 (es) Una composicion para enjuagar el cabello
BR9812756A (pt) Processo para produzir uma composição detergente granular de densidade elevada contendo tensoativos ramificados de cadeias médias
BE884848A (fr) Sel mixte d'acide valproique utile notamment pour le traitement de l'epilepsie, presentant des caracteristiques tres superieures de stabilite
ES2136255T3 (es) Alcohol polivinilico extrusionado, que contiene un perfume y su utilizacion.
BRPI0412592A (pt) formulação farmacêutica estável
AU1867983A (en) Substituted benzenesulfonic esters
BR9914919A (pt) Composição lìquida aquosa
JPS55139313A (en) Gel cream composition comprising higher fatty acid ethanol amide, and drug containing it
RU2001120110A (ru) Фармацевтическая смесь, содержащая профен
JPS5735509A (en) Analgesic and antiphlogistic cream
JPS55115859A (en) Carboxylic ester, its preparation, insecticide and acaricide with low toxicity to fish comprising it as active constituent
JPS55129220A (en) Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability
JPS57142906A (en) Insecticide

Legal Events

Date Code Title Description
FG Grant, registration